Please check your internet connection and try again.
## Ticagrelor (Brilinta)
### Overview
Ticagrelor is a direct-acting, reversible P2Y12 receptor antagonist that inhibits platelet activation and aggregation.
### Primary Indications
* **Acute Coronary Syndrome (ACS):** To reduce the rate of thrombotic cardiovascular events (including myocardial infarction and stroke) in patients with a history of ACS.
* **Established Cardiovascular Disease:** To reduce the rate of new cardiovascular events in patients with a history of myocardial infarction (MI).
### Adult Dosing
* **ACS:**
* **Loading Dose:** 180 mg orally once.
* **Maintenance Dose:** 90 mg orally twice daily for at least 12 months, or until discontinuation due to significant bleeding or other tolerability issues. In some patients, continuing beyond 12 months may be considered.
* **Established Cardiovascular Disease (post-MI):** 60 mg orally twice daily.
### Pediatric Dosing
Dosing for pediatric patients is not established.
### Dose Adjustments
No dose adjustment is necessary for patients with hepatic or renal impairment.
### Contraindications
* Active serious bleeding.
* History of intracranial hemorrhage.
* Known hypersensitivity to ticagrelor or any of its excipients.
### Adverse Effects
* **Most Common:** Dyspnea, bradyarrhythmia, accidental trauma, hypertension, bruising, bleeding (including life-threatening).
* **Serious:** Severe bleeding, ventricular pauses, increased serum creatinine, hyperuricemia.
### Key Drug Interactions
* **CYP3A4 Inhibitors/Inducers:** Ticagrelor is a substrate of CYP3A4. Concomitant use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) can increase ticagrelor exposure and risk of bleeding. Concomitant use with strong CYP3A4 inducers (e.g., rifampin, carbamazepine) can decrease ticagrelor exposure and efficacy.
* **P-gp Inhibitors:** Ticagrelor is a substrate of P-gp. Concomitant use with strong P-gp inhibitors can increase ticagrelor exposure.
* **Other Antiplatelet Agents/Anticoagulants:** Concomitant use increases the risk of bleeding.
* **Statins:** Increased simvastatin/atorvastatin exposure when used with ticagrelor. Avoid simvastatin >40 mg daily and atorvastatin >80 mg daily.
* **Aspirin:** Co-administration with aspirin is generally recommended for ACS, but the optimal duration with ticagrelor should be individualized. Long-term use of aspirin in patients treated with ticagrelor for established CV disease (post-MI) may increase bleeding risk without clear benefit.
* **Digoxin:** Ticagrelor can increase digoxin levels by inhibiting P-gp. Monitor digoxin levels.
### Monitoring
* **Bleeding:** Assess for signs and symptoms of bleeding regularly.
* **Renal Function:** Monitor serum creatinine.
* **Uric Acid:** Monitor serum uric acid levels, especially in patients with a history of gout or hyperuricemia.
* **Heart Rate:** Patients may experience bradycardia. ECG monitoring is not routinely recommended but consider in symptomatic patients.
### Clinical Pearls
* Dyspnea is a common side effect and is usually transient. It does not necessarily indicate underlying cardiac disease and does not typically require discontinuation.
* Ticagrelor is a reversible P2Y12 inhibitor, which may be advantageous in situations requiring temporary cessation of antiplatelet therapy (e.g., before surgery).
* The 60 mg twice-daily dose for established cardiovascular disease (post-MI) is a different indication and dose than for ACS.
* Drug interactions with CYP3A4 substrates and inhibitors are significant and require careful consideration.
***
*This information is intended for healthcare professionals. It is essential to consult the most current prescribing information and relevant clinical guidelines for definitive patient management decisions. Dosing and duration of therapy can vary based on individual patient factors, clinical presentation, and local protocols.*
